Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 13/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23628774 | 1.00 | TLR8 (0.44) | TLR8TLR9TLR7CYP3A4CYP1A2 | |
| SCHEMBL23628772 | 1.00 | TLR8 (0.44) | TLR8TLR9TLR7CYP3A4CYP1A2 | |
| SCHEMBL23628823 | 0.92 | TLR8 (0.42) | TLR8TLR9TLR7CYP3A4CYP1A2 | |
| SCHEMBL23628825 | 0.92 | TLR8 (0.42) | TLR8TLR9TLR7CYP3A4CYP1A2 | |
| SCHEMBL23628821 | 0.92 | TLR8 (0.42) | TLR8TLR9TLR7CYP3A4CYP1A2 | |
| SCHEMBL23628830 | 0.92 | TLR8 (0.44) | TLR8TLR9TLR7CYP3A4ALDH1A1 | |
| SCHEMBL23628826 | 0.92 | TLR8 (0.44) | TLR8TLR9TLR7CYP3A4ALDH1A1 | |
| SCHEMBL23628827 | 0.92 | TLR8 (0.44) | TLR8TLR9TLR7CYP3A4ALDH1A1 | |
| SCHEMBL23760739 | 0.88 | TLR8 (0.50) | TLR8TLR9TLR7CYP3A4CYP1A2 | |
| SCHEMBL23628869 | 0.88 | TLR9 (0.45) | TLR8TLR9TLR7CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-08-19 | — | — | US | claimed |
| EP-3847165-A1 | NOVEL PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-14 | — | — | EP | claimed |
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3847165-A1 | NOVEL PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, PRMT1, PADI1 | TLR8 1800/4885TLR9 308/4885TLR7 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.